Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CTSL | P07711 | 4/20 | 0.53 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.49 |
| ▸ | CTSS | P25774 | 15/20 | 0.48 |
| ▸ | CTSK | P43235 | 14/20 | 0.48 |
| ▸ | PPARG | P37231 | 1/20 | 0.47 |
| ▸ | PPARA | Q07869 | 1/20 | 0.47 |
| ▸ | ACE | P12821 | 1/20 | 0.47 |
| ▸ | CTSB | P07858 | 4/20 | 0.47 |
| ▸ | TRPA1 | O75762 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL25345326 | 1.00 | CTSL (0.53) | CTSLPTPN1CTSSCTSKPPARG | |
| SCHEMBL29481061 | 0.90 | CTSL (0.50) | CTSLCTSSCTSKCTSBTRPA1 | |
| SCHEMBL27207487 | 0.84 | PPARA (0.51) | CTSLPTPN1CTSSCTSKPPARG | |
| SCHEMBL29907919 | 0.84 | CTSS (0.60) | CTSLPTPN1CTSSCTSKPPARG | |
| SCHEMBL27203760 | 0.84 | PPARA (0.51) | CTSLPTPN1CTSSCTSKPPARG | |
| SCHEMBL17912348 | 0.84 | CTSS (0.60) | CTSLPTPN1CTSSCTSKPPARG | |
| SCHEMBL3812344 | 0.84 | CTSS (0.60) | CTSLPTPN1CTSSCTSKPPARG | |
| SCHEMBL3812341 | 0.84 | CTSS (0.60) | CTSLPTPN1CTSSCTSKPPARG | |
| SCHEMBL29842925 | 0.84 | CTSS (0.60) | CTSLPTPN1CTSSCTSKPPARG | |
| SCHEMBL31276738 | 0.83 | CTSS (0.53) | CTSLPTPN1CTSSCTSKPPARG |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | NATIONAL INSTITUTES OF HEALTH (NIH), U.S. DEPT. OF HEALTH AND HUMAN SERVICES (DHHS), U.S. GOVERNMENT | 2024-03-14 | — | — | US | disclosed |
| EP-4225730-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | The Regents of the University of California (US) | 2023-08-16 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20240083839-A1 | COMPOSITIONS AND METHODS FOR TREATING NEURODEGENERATIVE DISEASES AND DISORDERS | PRMT8, SIRT1, PRMT3 | CTSL 4256/4885PTPN1 3988/4885CTSS 3397/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.